MedTrace Logo

Ranibizumab Supplementing Panretinal Photocoagulation as Treatment for Iris/Angle Neovascularization in Retinal Ischemic Disease

NCT00841373 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 1

Last updated 2014-11-19

No results posted yet for this study

Summary

The object of the study is to compare treatment of iris/angle neovascularization with panretinal photocoagulation (laser) to treatment with panretinal photocoagulation and an anti-angiogenic drug: ranibizumab.

Conditions

  • Retinal Ischemia

Interventions

PROCEDURE

Panretinal Photocoagulation

Panretinal Photocoagulation treatment

PROCEDURE

Panretinal Photocoagulation and intravitreal injection of ranibizumab

Panretinal photocoagulation and ranibizumab

Sponsors & Collaborators

  • Genentech, Inc.

    collaborator INDUSTRY

  • Southern New England Retina Associates

    lead OTHER

Principal Investigators

  • Magdalena G Krzystolik, MD · Southern New England Retina Associates

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2007-07-31
Primary Completion
2009-01-31
Completion
2010-01-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00841373 on ClinicalTrials.gov